Minimally Invasive Surgery Compared to Laparotomy After Chemotherapy for Advanced Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

What this Trial Is About

Researchers are evaluating whether minimally invasive surgery MIS is as effective as the traditional open surgery method called laparotomy in treating women with advanced stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer. This phase III trial focuses on patients receiving chemotherapy before and after surgery, known as neoadjuvant chemotherapy. The study aims to see if MIS can provide similar disease control and quality of life benefits compared to laparotomy. Participants are randomly assigned to one of two groups. One group undergoes MIS within six weeks after completing 3 to 4 cycles of neoadjuvant chemotherapy if needed, the surgeon may switch to laparotomy during the procedure. The other group receives laparotomy within the same timeframe. After surgery, all patients continue standard chemotherapy within six weeks. The trial includes follow-up visits to monitor health and disease status over several years. During the study, participants have various assessments including quality of life questionnaires and evaluations of surgical outcomes like tumor removal success and complications. Researchers track disease-free survival up to five years and overall survival, along with surgical risks and healthcare costs. Follow-up occurs shortly after post-surgery chemotherapy, then every three months for two years, and every six months for an additional three years to monitor long-term health.

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial